REMARKS/ARGUMENTS

The Examiner has required restriction to one of the following inventions:

- I. Claims 29-31, 34 (in part), 35 (in part), 36 (in part) and 37 (in part), drawn to polypeptides.
- II. Claims 32, 33, 34 (in part), 35 (in part), 36 (in part) and 37 (in part), drawn to antibody.
- III. Claims 34 (in part), 35 (in part), 36 (in part) and 37 (in part), drawn to an agonist.
- IV. Claims 34 (in part), 35 (in part), 36 (in part) and 37 (in part), drawn to an antagonist.
- V. Claims 38 (in part) and 39 (in part), drawn to a method of treating an immune related disorder comprising administering a polypeptide.
- VI. Claims 38 (in part) and 39 (in part), drawn to a method of treating an immune related disorder comprising administering an agonist.
- VII. Claims 38 (in part) and 39 (in part), drawn to a method of treating an immune related disorder comprising administering an antagonist.
- VIII. Claims 38 (in part) and 39 (in part), drawn to a method of treating an immune related disorder comprising administering an antibody.
 - IX. Claim 40 drawn to a method of detecting the presence of a polypeptide.
 - X. Claims 41-43 drawn to a method of diagnosing disease.

Applicants elect Group X with traverse, Claims 41-43 drawn to a method of diagnosing an immune related disease comprising detecting the level of expression of a gene encoding a PRO polypeptide.

Applicants have canceled Claims 1-40, which are directed to non-elected subject matter. Claims 44-52 are added. The amendments are fully supported by the specification and claims originally filed and do not introduce any new matter. Applicants reserve the right to pursue the canceled subject matters in a continuation, continuation-in-part, or a divisional application. Claims are pending after the amendment. Applicants respectfully request that the Examiner consider the amendment.

CONCLUSION

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned attorney at the telephone number shown below. Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. <u>50-4634</u> (referencing Attorney's Docket No. <u>GNE-0269 R1</u>).

Respectfully submitted,

Date: January 21, 2009

By: Panpan Gao (Reg. No. 43,626)

GOODWIN PROCTER LLP

135 Commonwealth Drive Menlo Park, California 94025 Telephone: (650) 752-3100 Facsimile: (650) 853-1038

LIBC/3496628.1